Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O43172
UPID:
PRP4_HUMAN
Alternative names:
PRP4 homolog; U4/U6 snRNP 60 kDa protein; WD splicing factor Prp4
Alternative UPACC:
O43172; O43445; O43864; Q5T1M8; Q96DG2; Q96IK4
Background:
The U4/U6 small nuclear ribonucleoprotein Prp4, also known as PRP4 homolog, U4/U6 snRNP 60 kDa protein, and WD splicing factor Prp4, is integral to pre-mRNA splicing. As a component of the U4/U6-U5 tri-snRNP complex, it plays a pivotal role in spliceosome assembly and the formation of the precatalytic spliceosome (spliceosome B complex).
Therapeutic significance:
Retinitis pigmentosa 70, a retinal dystrophy characterized by night vision blindness and progressive loss of visual field, is linked to mutations affecting Prp4. Understanding the role of U4/U6 small nuclear ribonucleoprotein Prp4 could open doors to potential therapeutic strategies for this condition.